РЕТИНОЛ-СВЯЗЫВАЮЩИЙ БЕЛОК 4 И ЕГО РОЛЬ КАК ЛАБОРАТОРНОГО БИОМАРКЕРА ПРИ СЕРДЕЧНО-СОСУДИСТЫХ ЗАБОЛЕВАНИЯХ (ОБЗОР ЛИТЕРАТУРЫ)

Аннотация

Сердечно-сосудистые заболевания (ССЗ) представляют собой глобальную медицинскую, социальную и экономическую проблему. В настоящее время ведется активный поиск новых биологических маркеров и терапевтических мишеней с целью разработки эффективных подходов к стратификации риска и вторичной профилактике сердечно-сосудистой патологии. Особый интерес исследователей привлекает ретинол-связывающий белок 4 (RBP4). Цель данной статьи – проанализировать
исследования, посвященные роли RBP4 как диагностического и прогностического лабораторного маркера при ССЗ. Согласно
результатам проведенных исследований, RBP4 является молекулой с перспективным диагностическим и прогностическим
потенциалом при ССЗ.

Annotation

Cardiovascular disease (CVD) is a global health, social and economic problem. Currently, there is an active search for new
biological markers and therapeutic targets in order to develop effective approaches to risk stratification and secondary prevention of
cardiovascular pathology. Of particular interest to researchers is retinol binding protein 4 (RBP4). The purpose of this article is to
review studies examining the role of RBP4 as a diagnostic and prognostic laboratory marker in CVD. According to the results of the
studies, RBP4 is a molecule with promising diagnostic and prognostic potential in CVD.

Об авторах

Список литературы

ЛИТЕРАТУРА ( п п . 1 , 2 , 7 — 1 5 , 1 7 — 3 2 , 3 4 — 5 0
с м . REFERENCES )
3. Алиева А.М., Кисляков В.А., Воронкова К.В., Резник Е.В., Аракелян Р.А., Сарыев М.Н. и др. Интерлейкин 1 — биологический маркер при сердечной недостаточности. Архивъ внутренней медицины.
2022; 12 (6): 422-9. DOI: 10.20514/2226-6704-2022-12-6-422-429.
4. Голухова Е. З., Теряева Н. Б., Алиева А. М. Натрийуретические
пептиды — маркеры и факторы прогноза при хронической сердечной недостаточности. Креативная кардиология. 2007; 1-2: 126-36.
5. Алиева А.М., Чиркова Н.Н., Пинчук Т.В., Андреева О.Н., Пивоваров В.Ю. Эндотелины и сердечно-сосудистая патология.
Российский кардиологический журнал. 2014; (11): 83-7. DOI:
10.15829/1560-4071-2014-11-83-87.
6. Алиева А.М., Резник Е.В., Пинчук Т.В., Аракелян Р.А., Валиев Р.К., Рахаев А.М. и др. Фактор дифференцировки роста-15
(GDF-15) как биологический маркер при сердечной недостаточности. Архивъ внутренней медицины. 2023; 13 (1): 14-23. DOI:
10.20514/2226-6704-2023-13-1-14-23.
16. Бородкина Д.А, Груздева О.В., Белик Е.В., Паличева Е.И., Кузьмина А.А. Перспективы использования ретинол-связывающего
белка в качестве биомаркера риска кардиоваскулярной патологии. Клиническая лабораторная. диагностика. 2018; 63 (2): 79-84.
DOI: 10.18821/0869-2084-2018-63-2-79-84.
33. Васюк Ю.А., Садулаева И.А., Ющук Е.Н., Трофименко О.С., Иванова С.В. Ретинол-связывающий белок как маркер сердечно-сосудистого риска у пациентов с артериальной гипертензией и ожирением. Российский кардиологический журнал. 2018;(4):14-18.
DOI:10.15829/1560-4071-2018-4-14-18
REFERENCES
1. Timmis A., Townsend N., Gale C.P., Torbica A., Lettino M., Petersen
S.E. et al. European Society of Cardiology: Cardiovascular Disease
Statistics 2019. Eur. Heart J. 2020; 41 (1): 12-85. DOI: 10.1093/
eurheartj/ehz859.
2. Baigent C., Koskinas K.C., Casula M., Badimon L., Chapman M.J.,
Backer G.G.D., Delgado V., Ference B.A., Graham I.M., Halliday
A., et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. Eur.
Heart J. 2020; 41:11–188. DOI: 10.1093/eurheartj/ehz455.
3. Alieva A.M., Kislyakov V.A., Voronkova K.V., Reznik E.V., Arakelyan R.A., Saryev M.N. et al. Interleukin-1 is a Biological Marker
in Heart Failure. Arkhivъ vnutrenney meditsiny. 2022; 12 (6): 422-9.
DOI: 10.20514/2226-6704-2022-12-6-422-429. (in Russian)
4. Golukhova E. Z., Teryaeva N. B., Alieva A. M. Natriuretic peptides
— markers and prognosis factors in chronic heart failure. Kreativnaya
kardiologiya. 2007; 1-2: 126-36. (in Russian)
5. Alieva A.M., Chirkova N.N., Pinchuk T.V., Andreeva O.N., Pivovarov V.Yu. Endothelines and cardiovascular pathology. Rossiyskiy
kardiologicheskiy zhurnal. 2014; (11): 83-7. DOI: 10.15829/1560-
4071-2014-11-83-87. (in Russian)
6. Alieva A.M., Reznik E.V., Pinchuk T.V., Arakelyan R.A., Valiev
R.K., Rakhaev A.M. et al. Growth Differentiation Factor-15 (GDF15) is a Biological Marker in Heart Failure. Arkhivъ vnutrenney
meditsiny. 2023; 13 (1): 14-23. DOI: 10.20514/2226-6704-2023-
13-1-14-23. (in Russian)
7. Rychter A.M., Skrzypczak-Zielińska M., Zielińska A., Eder P., Souto
E.B., Zawada A. et al. Is the Retinol-Binding Protein 4 a Possible
Risk Factor for Cardiovascular Diseases in Obesity? Int. J. Mol. Sci.
2020 ; 21 (15): 5229. DOI: 10.3390/ijms21155229.
8. Ji Y., Song J., Su T., Gu X. Adipokine Retinol Binding Protein 4 and
Cardiovascular Diseases. Front Physiol. 2022; 13: 856298. DOI:
10.3389/fphys.2022.856298.
9. Oluwamodupe C., Adeleye A.O. Targeting Retinol-Binding Protein
4 (RBP4) in the Management of Cardiometabolic Diseases. Cardiovasc. Toxicol. 2023; 23 (9-10): 285-94. DOI: 10.1007/s12012-023- 09803-8.
10. Hamilton J.A., Benson M.D. Transthyretin: a review from a structural perspective. Cell Mol. Life Sci. 2001; 58 (10): 1491-1521.
DOI: 10.1007/PL00000791.
11. Nono Nankam P.A., Blüher M. Retinol-binding protein 4 in obesity and metabolic dysfunctions. Mol. Cell Endocrinol. 2021; 531:
111312. DOI: 10.1016/j.mce.2021.111312.
12. Steinhoff J.S., Lass A., Schupp M. Retinoid Homeostasis and Beyond: How Retinol Binding Protein 4 Contributes to Health and Disease. Nutrients. 2022; 14 (6): 1236. DOI: 10.3390/nu14061236.
13. Flores-Cortez Y.A., Barragán-Bonilla M.I., Mendoza-Bello J.M.,
González-Calixto C., Flores-Alfaro E., Espinoza-Rojo M. Interplay
of retinol binding protein 4 with obesity and associated chronic alterations (Review). Mol. Med. Rep. 2022; 26 (1): 244. DOI: 10.3892/
mmr.2022.12760.
14. Napoli J.L. Functions of intracellular retinoid binding-proteins.
Subcell. Biochem. 2016; 81: 21-76. DOI: 10.1007/978-94-024-
0945-1_2.
15. Grosjean F., Esposito P., Maccarrone R., Libetta C., Dal Canton A.,
Rampino T. RBP4: A culprit for insulin resistance in end stage renal
disease that can be cleared by hemodiafiltration. BioMed. Res. Int.
2017; 2017: 7270595. DOI: 10.1155/2017/7270595.
16. Borodkina D.A., Gruzdeva O.V., Belik E.V., Palicheva E.I., Kuzmina
A.A. Prospects for using retinol-binding protein as a biomarker
of cardiovascular disease risk. Klinicheskaya laboratornaya
diagnostika. 2018; 63 (2): 79-84. DOI: 10.18821/0869-2084-2018-
63-2-79-84. (in Russian)
17. Wang J., Chen H., Liu Y., Zhou W., Sun R., Xia M. Retinol binding
protein 4 induces mitochondrial dysfunction and vascular oxidative
damage. Atherosclerosis. 2015; 240 (2): 335-44. DOI: 10.1016/j.
atherosclerosis.2015.03.036.
18. Norseen J., Hosooka T., Hammarstedt A., Yore M.M., Kant S.,
Aryal P. et al. Retinol-binding protein 4 inhibits insulin signaling in
adipocytes by inducing proinflammatory cytokines in macrophages
through a c-Jun N-terminal kinase- and toll-like receptor 4-dependent
and retinol-independent mechanism. Mol. Cell Biol. 2012; 32 (10):
2010-9. DOI: 10.1128/MCB.06193-11.
19. Farjo K.M., Farjo R.A., Halsey S., Moiseyev G., Ma J.X. Retinolbinding protein 4 induces inflammation in human endothelial cells
by an NADPH oxidase- and nuclear factor kappa B-dependent and
retinol-independent mechanism. Mol. Cell Biol. 2012; 32 (24):
5103-15. DOI: 10.1128/MCB.00820-12.
20. Li F., Xia K., Sheikh S.A., Cheng J., Li C., Yang T. Involvement
of RBP4 in hyperinsulinism-induced vascular smooth muscle cell
proliferation. Endocrine. 2015; 48 (2): 472-82. DOI: 10.1007/
s12020-014-0304-0.
21. Usui S., Ichimura M., Ikeda S., Okamoto M. Association between
serum retinol-binding protein 4 and small dense low-density
lipoprotein cholesterol levels in young adult women. Clin. Chim.
Acta. 2009; 399 (1-2): 45-8. DOI: 10.1016/j.cca.2008.08.017.
22. Wu J., Shi Y.H., Niu D.M., Li H.Q., Zhang C.N., Wang J.J. Association
among retinol-binding protein 4, small dense LDL cholesterol and
oxidized LDL levels in dyslipidemia subjects. Clin. Biochem. 2012;
45 (9): 619-22. DOI: 10.1016/j.clinbiochem.2012.02.022.
23. Wessel H., Saeed A., Heegsma J., Connelly M.A., Faber K.N.,
Dullaart R.P.F. Plasma Levels of Retinol Binding Protein 4 Relate to
Large VLDL and Small LDL Particles in Subjects with and without
Type 2 Diabetes. J. Clin. Med. 2019; 8 (11): 1792. DOI: 10.3390/
jcm8111792.
24. Codoñer-Franch P., Carrasco-Luna J., Allepuz P., Codoñer-Alejos
A., Guillem V. Association of RBP4 genetic variants with childhood
obesity and cardiovascular risk factors. Pediatr. Diabetes. 2016; 17
(8): 576-83. DOI: 10.1111/pedi.12339.
25. Won J.C., Park C.Y., Oh S.W., Park S.W. Increased plasma levels
of retinol-binding protein 4 with visceral obesity is associated with
cardiovascular risk factors. J. Diabetes Investig. 2012; 3 (5): 457-63.
DOI: 10.1111/j.2040-1124.2012.00213. x.
26. Karamfilova V., Gateva A., Alexiev A., Zheleva N., Velikova T.,
Ivanova-Boyanova R. et al. The association between retinol-binding
protein 4 and prediabetes in obese patients with nonalcoholic fatty
liver disease. Arch. Physiol. Biochem. 2022; 128 (1): 217-22. DOI:
10.1080/13813455.2019.1673429.
27. Xiang J., Dai H., Hou Y., Wang Q., Wang T., Li M. et al. Sexual
Dimorphism in the Association of Serum Retinol-Binding Protein-4
With Long-Term Dynamic Metabolic Profiles in Non-Diabetes.
Front. Endocrinol. (Lausanne). 2022; 13: 880467. DOI: 10.3389/
fendo.2022.880467.
28. Frances L., Tavernier G., Viguerie N. Adipose-Derived LipidBinding Proteins: The Good, the Bad and the Metabolic Diseases.
Int. J. Mol. Sci. 2021; 22 (19): 10460. DOI: 10.3390/ijms221910460.
29. Li X., Zhu S., Song G., Zhang K., Gao W., Huang J. et al. Retinolbinding protein 4 is closely correlated to blood pressure level and
E/A in untreated essential hypertension patients. Ann. Palliat. Med.
2019; 8 (5): 645-50. DOI: 10.21037/apm.2019.11.07.
30. Zhang J.X., Zhu G.P., Zhang B.L., Cheng Y.Y. Elevated serum
retinol-binding protein 4 levels are correlated with blood pressure in
prehypertensive Chinese. J. Hum. Hypertens. 2017; 31 (10): 611-5.
DOI: 10.1038/jhh.2017.44.
31. Chondrou A., Nigdelis M.P., Armeni E., Augoulea A., Rizos D.,
Kaparos G. et al. Retinol-binding protein 4 is associated with arterial
stiffness in early postmenopausal women. Menopause. 2020; 27 (8):
906-12. DOI: 10.1097/GME.0000000000001598.
32. Li B., Hou C., Li L., Li M., Gao S. The associations of adipokines
with hypertension in youth with cardiometabolic risk and the
mediation role of insulin resistance: The BCAMS study. Hypertens.
Res. 2023; 46 (7): 1673-83. DOI: 10.1038/s41440-023-01243-9.
33. Vasyuk Yu.A., Sadulaeva I.A., Yushchuk E.N., Trofimenko
O.S., Ivanova S.V. Retinol-binding protein as a marker of
cardiovascular risk in patients with arterial hypertension and obesity.
Rossijskij kardiologicheskij zhurnal. 2018;(4):14-18. https://doi.
org/10.15829/1560-4071-2018-4-14-18. (in Russian)
34. Fazlıoğlu N., Uysal P., Durmus S., Yurt S., Gelisgen R., Uzun H.
Significance of plasma risin, adiponectin, and retinol binding
protein-4 levels as biomarkers for obstructive sleep apnea syndrome
severity. Biomolecules. 2023; 13 (10): 1440. DOI: 10.3390/
biom13101440.
35. Liu T., Han C., Sun L., Ding Z., Shi F., Wang R. et al. Association
between new circulating proinflammatory and anti-inflammatory
adipocytokines with coronary artery disease. Coron. Artery Dis.
2019; 30 (7): 528-35. DOI: 10.1097/MCA.0000000000000778.
36. Liu Y., Wang D., Chen H., Xia M. Circulating retinol binding
protein 4 is associated with coronary lesion severity of patients with
coronary artery disease. Atherosclerosis. 2015; 238 (1): 45-51. DOI:
10.1016/j.atherosclerosis.2014.11.016.
37. Christou G.A., Andriopoulou C.E., Liakopoulou A., Tsape E.,
Apostolakis E., Tselepis A.D. et al. Unraveling the role of resistin,
retinol-binding protein 4 and adiponectin produced by epicardial
adipose tissue in cardiac structure and function: evidence of a
paracrine effect. Hormones (Athens). 2023; 22 (2): 321-30. DOI:
10.1007/s42000-023-00447-5.
38. Wan K., Zhao J., Deng Y., Chen X., Zhang Q., Zeng Z. et al. A
genetic polymorphism in RBP4 is associated with coronary artery
disease. Int. J. Mol. Sci. 2014; 15 (12): 22309-19. DOI: 10.3390/
ijms151222309.
39. Liu T., Han C., Sun L., Ding Z., Shi F., Wang R. et al. Association
between new circulating proinflammatory and anti-inflammatory
adipocytokines with coronary artery disease. Coron. Artery Dis.
2019; 30 (7): 528-35. DOI: 10.1097/MCA.0000000000000778.
40. Li J., Huang X., Jiang Y., Luo F., Mao Z. Expression and clinical
significance of serum retinol binding protein 4, superoxide
dismutase and hypersensitive C-reactive protein in patients with
acute ST-segment elevated myocardial infarction. Zhonghua Wei
Zhong Bing Ji Jiu Yi Xue. 2020; 32 (10): 1199-1202. DOI: 10.3760/
cma.j.cn121430-20200113-00132.
41. Si Y., Liu J., Han C., Wang R., Liu T., Sun L. The correlation of
retinol-binding protein-4 and lipoprotein combine index with the
prevalence and diagnosis of acute coronary syndrome. Heart Vessels.
2020; 35 (11): 1494-501. DOI: 10.1007/s00380-020-01627-8.
42. Xu H., Ding Z., Chen J., Zhang Y., Shan W., Chen X. et al. Correlation
between serum Dickkopf-1 (DKK1) levels and coronary artery
stenosis. Nutr. Metab. Cardiovasc. Dis. 2023; 33 (1): 168-76. DOI:
10.1016/j.numecd.2022.10.007.
43. Nar G., Sanlialp S.C., Nar R. Retinol binding protein 4 levels relate
to the presence and severity of coronary artery disease. J. Med.
Biochem. 2021; 40 (4): 384-9. DOI: 10.5937/jomb0-28846.
44. Ye B., Zhao Q., Fan J., Li X., Shan C., Liu F. et al. RBP4-based
Multimarker Score: A prognostic tool for adverse cardiovascular
events in acute coronary syndrome patients. J. Clin. Endocrinol. Metab. 2023; 108 (12): 3111-21. DOI: 10.1210/clinem/dgad389.
45. Qian K., Yan X., Xu C., Fang Y., Ma M. Association between
circulating retinol-binding protein 4 and adverse cardiovascular
events in stable coronary artery disease. Front. Cardiovasc. Med.
2022; 9: 829347. DOI: 10.3389/fcvm.2022.829347.
46. Wang Y., Zhou C., Yu T., Zhao F. Correlation between changes
in serum RBP4, hs-CRP, and IL-27 levels and rosuvastatin in the
treatment of coronary heart disease. J. Healthc. Eng. 2021; 2021:
8476592. DOI: 10.1155/2021/8476592.
47. Majerczyk M., Choręza P., Mizia-Stec K., Bożentowicz-Wikarek M.,
Brzozowska A., Arabzada H. et al. Plasma level of retinol-binding
protein 4, N-terminal proBNP and renal function in older patients
hospitalized for heart failure. Cardiorenal. Med. 2018; 8 (3): 237-48.
DOI: 10.1159/000489403.
48. Li X.Z., Zhang K.Z., Yan J.J., Wang L., Wang Y., Shen X.Y. et al. Serum retinol-binding protein 4 as a predictor of cardiovascular events
in elderly patients with chronic heart failure. ESC Heart Fail. 2020;
7 (2): 542-50. DOI: 10.1002/ehf2.12591.
49. An Y., Wang Q., Wang H., Zhang N., Zhang F. Clinical significance
of sFRP5, RBP-4 and NT-proBNP in patients with chronic heart failure. Am. J. Transl. Res. 2021; 13 (6): 6305-11.
50. Chavarria N., Kato T.S., Khan R., Chokshi A., Collado E., Akashi
H. et al. Increased levels of retinol binding protein 4 in patients with
advanced heart failure correct after hemodynamic improvement
through ventricular assist device placement. Circ. J. 2012; 76 (9):
2148-52. DOI: 10.1253/circj. cj-12-0350.

Ключевые слова